ZBTB39: A Potential Drug Target and Biomarker (G9880)

Target Name: ZBTB39

NCBI ID: G9880

ZBTB39

ZBTB39: A Potential Drug Target and Biomarker

Zinc finger and BTB domain containing 39 (ZBTB39) is a protein that has been identified as a potential drug target and biomarker. ZBTB39 is a 39-kDa protein that is expressed in various tissues and cell types, including brain, heart, and muscle. It is characterized by the presence of a zinc finger and a BTB domain. The zinc finger is a conserved structural domain that is found in a variety of proteins, including transcription factors, while the BTB domain is a unique structural domain that is found in proteins that interact with the BTB domain-containing protein 1 (BTB1).

The discovery of ZBTB39 as a potential drug target and biomarker comes from a study by the research group of Dr. Qin Liu at the University of California, San Diego. The study identified ZBTB39 as a potential drug target by using a variety of techniques, including cell-based assays, in vitro drug screening, and biochemical assays. The researchers found that ZBTB39 was a potent inhibitor of the androgen receptor, a protein that plays a key role in the development and maintenance of male sexual characteristics.

In addition to its potential as a drug target, ZBTB39 has also been identified as a potential biomarker. The BTB domain is known for its ability to interact with other proteins, including the BTB1 protein. This interaction suggests that ZBTB39 may be able to interact with BTB1 and potentially regulate its activity. The researchers used a variety of techniques to investigate the BTB1-ZBTB39 interaction, including biochemical assays, cell-based assays, and in vitro drug screening. They found that the interaction between ZBTB39 and BTB1 was dose-dependent and required for the activity of ZBTB39.

The identification of ZBTB39 as a potential drug target and biomarker also has implications for the development of new treatments for various diseases. The androgen receptor is involved in the development and maintenance of male sexual characteristics, and the involvement of ZBTB39 in this pathway suggests that it may be a useful target for the development of male-specific treatments. The researchers are currently working on developing small molecules that can inhibit the activity of ZBTB39 and are investigating the potential efficacy of these small molecules in animal models of prostate cancer.

In conclusion, ZBTB39 is a protein that has been identified as a potential drug target and biomarker. The zinc finger and BTB domain containing 39 is characterized by the presence of a zinc finger and a BTB domain, which suggests that it may interact with other proteins . The researchers have identified ZBTB39 as a potent inhibitor of the androgen receptor and are currently working on developing small molecules that can inhibit its activity. ZBTB39 may be a useful target for the development of new treatments for various diseases.

Protein Name: Zinc Finger And BTB Domain Containing 39

Functions: May be involved in transcriptional regulation

The "ZBTB39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets